Healthcare
VolitionRx Limited(VNRX)
Live Price
Offline$1.43
+4.38% today
1Y Change
-91.98%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $10.00M
- Revenue Growth
- +40.0%
- EPS Growth
- +29.0%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
VolitionRx Limited (VNRX) is a Healthcare stock with a market cap of $10.00M and listed on AMEX. The stock last traded around $1.43 and down 92.0% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +40.0%, EPS growth of +29.0%, a dividend yield of 0.0%. What stands out right now is revenue +40.0%, EPS +29.0%, free cash flow +25.3% with operating margin -1253.4% and ROIC 1261.8%. Valuation sits in the middle of the pack at price/sales 7.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VNRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+40.0% vs +7.6% peer median
Operating Margin
Below sector median
-1253.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 14, 2026 with an EPS surprise of -38.6% and a revenue surprise of -35.2%.
The operating story is still moving forward
Revenue is running at +40.0% and EPS at +29.0%, with operating margin around -1253.4%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 13, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 2 reported quarters, the stock averaged +3.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | -38.6% | -9.1% | +22.7% | -37.3% |
2026 Mar 31, 2026 | -42.9% | +0.0% | -15.0% | -34.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VNRX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VNRX Max Drawdown
-92.18%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VNRX and SPY.
Company Overview
VolitionRx Limited
New York Stock Exchange American
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
- Leadership
- Cameron Reynolds
- IPO Date
- Mar 2, 2012
- Employees
- 85
- Street Address
- 13215 Bee Cave Parkway
- Mailing
- Henderson, TX, 78738
- Region
- Henderson, TX, US
- Reporting Currency
- USD
- Investor Line
- 646 650 1351
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 7.4
- Price/Book
- โ
Growth
- Revenue
- +40.0%
- EPS
- +29.0%
- Free Cash Flow
- +25.3%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -1253.4%
- Net Margin
- -1352.2%
- ROE
- 72.7%
- ROIC
- 1261.8%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.17
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.